Recursion Q3 revenue $26.1M, net loss $95.8M; Exscientia merger on track

RECURSION PHARMACEUTICALS, INC.

2024-Q3 EPS reported -$1.12 revenue$54,293,000

Revenue surged to $26.1M from $10.5M YoY; net loss $95.8M vs $93.0M; no EPS provided.
Cash and equivalents $427.6M as of Sep 30, 2024; net cash used in operations $59.2M.
Roche-Genentech optioned first neuroscience phenomap for $30M; total potential $500M across multiple maps.
Proposed Exscientia merger: shareholder vote Nov 12; scheme of arrangement expected Nov 20, 2024.
Clinical milestones: Phase 2 CCM data encouraging; IND cleared for REC-1245; first patient dosed in Phase 2 C. diff.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.